Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Eyestil Plus is a preservative-free ophthalmic solution developed by SIFI for the management of moderate-to-severe dry eye syndrome. It is a combination product containing 0.4% sodium hyaluronate and 0.5% taurine. Sodium hyaluronate, a high-molecular-weight glycosaminoglycan, provides viscoelastic and mucoadhesive properties that stabilize the tear film and lubricate the ocular surface. Taurine acts as an osmoprotectant, helping corneal epithelial cells maintain volume and integrity under hyperosmotic conditions typical of dry eye, and provides antioxidant protection against oxidative stress. The formulation is designed to provide long-lasting relief from symptoms such as burning and foreign body sensation while promoting the repair of the corneal epithelium.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Eyestil Plus.